Evidence map›Paper›PMID 42769185›Full record

ArticleFrontiers in dementia2026

From engagement to dissemination: a WiseAge patient and public involvement and engagement event on dementia with Lewy bodies.

Jon Arild Aakre, Arvid Rongve, Kari Fredriksen, Ellen J Svendsboe, Ingelin Testad

Abstract read
In one paragraph

Article in Frontiers in dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jon Arild AakreDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Arvid RongveDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Kari FredriksenCentre for Age-Related Medicine - SESAM, Stavanger University Hospital, Stavanger, Norway.
Ellen J SvendsboeDepartment of Health- and Social Sciences, Western Norway University of Applied Sciences, Stord, Norway.
Ingelin TestadCentre for Age-Related Medicine - SESAM, Stavanger University Hospital, Stavanger, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dementia with Lewy bodies may account for up to 20% of dementia cases, yet public awareness remains limited. Public engagement may help communicate dementia research to wider audiences, but little is known about whether information spreads beyond event attendees. This study explored how attendees evaluated information about dementia with Lewy bodies and the ongoing Ambroxol in New and Early Dementia with Lewy Bodies (ANeED) clinical drug trial presented at a WiseAge public engagement event, and how they reported sharing this information afterwards. Methods: This descriptive cross-sectional study followed a WiseAge public engagement event that included information about dementia, dementia with Lewy bodies, and the clinical trial. A post-event survey was distributed to attendees, and responses were analysed descriptively. Results: Of 48 attendees, 18 completed the survey. The information was rated positively, with 16 of 18 rating it as good or very good. Attendees reported sharing information beyond the event, most commonly with friends ( Conclusion: The event was well received and supported secondary dissemination through attendees' interpersonal networks, particularly friends and family. Although no immediate recruitment effect was observed, public engagement may extend the reach of dementia research communication beyond those who attend.

Indexed as

ANeED clinical drug trialdementia researchdementia with Lewy bodiespatient and public involvement and engagementsecondary disseminationWiseAge

Identifiers

PMID42769185
PMCPMC13590376

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.